Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.
Ramez N EskanderMichael W SillLindsey BeffaRichard G MooreJoanie M HopeFernanda B MusaRobert MannelMark S ShahinGuilherme H CantuariaEugenia GirdaCara MathewsJuraj KavecanskyCharles A LeathLilian T GienEmily M HinchcliffShashikant B LeleLisa M LandrumFloor BackesRoisin E O'CearbhaillTareq Al BaghdadiEmily K HillPremal H ThakerVeena S JohnStephen WelchAmanda N FaderMatthew A PowellCarol AghajanianPublished in: The New England journal of medicine (2023)
In patients with advanced or recurrent endometrial cancer, the addition of pembrolizumab to standard chemotherapy resulted in significantly longer progression-free survival than with chemotherapy alone. (Funded by the National Cancer Institute and others; NRG-GY018 ClinicalTrials.gov number, NCT03914612.).